AKR7L Antibody
357.5€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
AKR7L Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx037616
tested applications
ELISA, WB, IHC
Description
Rabbit Polyclonal against the AKR7L protein.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | AKR7L |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/20000 - 1/80000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by antigen affinity column chromatography. |
| Size 1 | 100 µg |
| Size 2 | 1 mg |
| Form | Lyophilized |
| Tested Applications | ELISA, WB, IHC |
| Buffer | Prior to lyophilization: 1% BSA and 0.02% NaN3. |
| Availability | Shipped within 7-15 working days. |
| Storage | Store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | NP_001138761.1 |
| Alias | AKR7L,AFAR3,AKR7A4 |
| Background | Antibody anti-AKR7L |
| Status | RUO |
| Note | Concentration: Lyophilized form: Not applicable. After reconstitution: 1 mg/ml. - |
Descripción
Aflatoxin B1 Aldehyde Reductase Member 4 (AKR7L) is an enzyme that belongs to the aldo-keto reductase (AKR) superfamily, which is involved in the detoxification of reactive aldehydes and ketones. AKR7L specifically catalyzes the reduction of aflatoxin B1 dialdehyde, a highly toxic and carcinogenic metabolite produced by aflatoxin B1, into less harmful compounds, thereby reducing its potential to cause DNA damage and cancer. This enzyme is primarily expressed in the liver, where it plays a critical role in protecting against oxidative stress and chemical toxicity. Dysregulation or deficiency of AKR7L has been linked to increased susceptibility to aflatoxin-induced hepatocellular carcinoma and other toxicant-related liver diseases. AKR7L is also involved in the detoxification of endogenous aldehydes generated during lipid peroxidation, highlighting its broader role in maintaining cellular redox balance. Research into AKR7L focuses on its potential as a therapeutic target to enhance detoxification processes and reduce the risk of aflatoxin-related liver cancer.
Related Products
Human Aflatoxin B1 aldehyde reductase member 4 (AKR7L) ELISA Kit
Human Aflatoxin B1 aldehyde reductase member 4 (AKR7L) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human Aflatoxin B1 aldehyde reductase member 4 (AKR7L) concentrations in serum, plasma, tissue homogenates, cell culture supernatants and other biological fluids.
Ver Producto